First-in-class immune proteasome inhibitor phase II results positive, stock price rose more than 60%

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On November 15, Kezar Life Sciences announced the mid-term results of its first-in-class selective immune proteasome inhibitor KZR-616 for the treatment of active, proliferative lupus nephritis (LN) MISSION study phase II trial

Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE)

KZR-616 is a new, first-in-class, selective immune proteasome inhibitor, which can regulate inflammation-driving factors of a variety of immune cell types, and has a wide range of therapeutic potential for a variety of autoimmune diseases

The MISSION (NCT03393013) trial is a phase Ib/II clinical trial.

At the time of the interim analysis, 5 patients had finished treatment and 10 patients had been treated for 13 weeks

The results of the interim analysis of the MISSION study showed that at week 25, 3 out of 5 patients had UPCR values ​​that were 50% or more lower than the baseline (primary efficacy endpoint)

At the 13th week of KZR-616 treatment, 5 out of 10 patients had clinically significant reductions in UPCR, including improvements in key disease biomarkers

In terms of safety, KZR-616 was well tolerated during the 6-month treatment period

Part of the top-line data of the Phase II trial of the MISSION study is expected to be released in the second quarter of 2022